APM	antigen-presenting machinery
ccRCC	clear cell renal cell carcinoma
CI	confidence interval
CR	complete response
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
DC	dendritic cell
HIF	hypoxia-inducible factors
ICI	immune checkpoint inhibitor
IFN-α	interferon-alfa
IL-2	interleukin-2
IMDC	International Metastatic Renal Cell Carcinoma Database Consortium
ITT	intention-to-treat
lncRNA	long non-coding RNA
MHC-I	major histocompatibility class I
MSKCC	Memorial Sloan Kettering Cancer Center
mTOR	mammalian target of the rapamycin
ORR	objective response rate
OS	overall survival
PD-1	programed cell death protein 1
PD-L1	ligand of programed cell death protein 1
PFS	progression-free survival
QoL	quality-of-life
TAM	tumor-associated macrophage
TCGA	The Cancer Genome Atlas
TKI	tyrosine kinase inhibitor
TLS	tertiary lymphoid structures
TME	tumor microenvironment
TRAEs	treatment-related adverse events
VEGF	vascular endothelial growth factor
VHL	Von Hippel-Lindau